Previous 10 | Next 10 |
Genmab (GMAB) and Seagen (SGEN) announce the submission of a Biologics License Application ((BLA)) to the U.S. FDA seeking accelerated approval for tisotumab vedotin for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or a...
- Submission Based on Positive Pivotal innovaTV 204 Trial Results Presented at the European Society of Medical Oncology Virtual Congress 2020 - Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced the submission of a Biologics License Application ...
Biotech stocks attracted maximum attention in 2020 due to the COVID-19 pandemic and a worldwide scramble to develop vaccines. Favorable news surrounding vaccines has boosted confidence generally that biotech companies will be successful in developing treatments for other critical diseases soo...
BMEZ delivered solid results throughout 2020, helped by the healthcare sector overall. This fund doesn't just invest in your typical healthcare companies though and tilts towards smaller and private investments. These companies are ripe for significant growth, at the same time, BM...
Genmab A/S ([[GMAB]] -1.5%) gets positive recommendation for marketing approval for its subcutaneous ofatumumab for the treatment of relapsing forms of multiple sclerosis in certain adults from the Committee for Medicinal Products for Human Use ((CHMP)).Ofatumumab is being developed and ...
Genmab A/S (GMAB) has announced that the FDA has approved DARZALEX FASPRO® to treat newly diagnosed Light-chain (“AL”) amyloidosis, a rare disease affecting an estimated ~3,000 to 4,000 individuals in the U.S. annually.Janssen Biotech, Inc. (Janssen) of Johnson & Johnso...
Genmab ([[GMAB]]) reached the first milestone in its collaboration with AbbVie with a $40M milestone payment triggered by the first patient dosed in the Phase 3 study of subcutaneous epcoritamab versus investigator's choice of chemotherapy in patients with relapsed or refractory diffuse ...
Cullinan Management (CGEM) has priced upsized initial public offering of 11.9M common shares at $21/share, for expected gross proceeds of ~$249.9M.The company previously planned to raise $195M by offering 10M shares at a price range of $19 to $20 above the original offering of 8.3M shares at ...
Genmab ([[GMAB]] -0.4%) announces initiation of innovaTV 301 Phase 3 trial evaluating tisotumab vedotin in patients with recurrent or metastatic cervical cancer who have received one or two prior lines of systemic therapy. The 482-subject study will evaluate efficacy of tisotumab compare...
Genmab is a well-managed and vast European biopharma R&D giant. Its partnered products and self-owned pipelines are vast. This is a stock to accumulate at dips. For further details see: Genmab: An European R&D Behemoth With Long-Term Potential
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 01:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...